Market revenue in 2023 | USD 155.1 million |
Market revenue in 2030 | USD 374.6 million |
Growth rate | 13.4% (CAGR from 2023 to 2030) |
Largest segment | Acute |
Fastest growing segment | Preventive |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Acute, Preventive |
Key market players worldwide | GlaxoSmithKline, Pfizer Inc, AbbVie Inc, Amgen Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd, Biohaven Ltd, Johnson & Johnson, Bausch Health Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to migraine drugs market will help companies and investors design strategic landscapes.
Acute was the largest segment with a revenue share of 63.31% in 2023. Horizon Databook has segmented the Italy migraine drugs market based on acute, preventive covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy migraine drugs market , including forecasts for subscribers. This country databook contains high-level insights into Italy migraine drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account